Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib in the Treatment of IgG4 Related Diseases
NCT07827469Completed
- Sponsor
- Peking University People's Hospital
- Start
- Apr 2023
- Primary completion
- Jun 2026
- Countries
- 1
01
Overview
Randomised, open-label trial of tofacitinib oral solution in immunoglobulin G4-related disease (IgG4-RD) (2 arms), sponsored by Peking University People's Hospital. Primary endpoint: IgG4-RD Remission Rate at 24 weeks. Started Apr 2023; status: completed.
02
Drugs
tofacitinib oral solution
03
Conditions
immunoglobulin G4-related disease (IgG4-RD)
Beyond the preview
Go deeper on NCT07827469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07827469.